OOIR: Observatory of International Research

Papers

(The H4-Index of Journal of Psychopharmacology is 30. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-11-01 to 2024-11-01.)

Article	Citations
Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: Prospective 12-month follow-up	213
Adverse effects of psychedelics: From anecdotes and misinformation to systematic science	135
Ketamine: A tale of two enantiomers	124
Pivotal mental states	83
Development of the Psychological Insight Questionnaire among a sample of people who have consumed psilocybin or LSD	74
Adverse events in clinical treatments with serotonergic psychedelics and MDMA: A mixed-methods systematic review	71
Transcriptional regulation in the rat prefrontal cortex and hippocampus after a single administration of psilocybin	66
First study of safety and tolerability of 3,4-methylenedioxymethamphetamine-assisted psychotherapy in patients with alcohol use disorder	64
Evidence-based consensus guidelines for the management of catatonia: Recommendations from the British Association for Psychopharmacology	61
Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience	60
Optimal dosing for psilocybin pharmacotherapy: Considering weight-adjusted and fixed dosing approaches	58
Efficacy and Tolerability of Combination Treatments for Major Depression: Antidepressants plus Second-Generation Antipsychotics vs. Esketamine vs. Lithium	57
The effects of psilocybin on cognitive and emotional functions in healthy participants: Results from a phase 1, randomised, placebo-controlled trial involving simultaneous psilocybin administration an	48
Mystical-type experiences occasioned by ketamine mediate its impact on at-risk drinking: Results from a randomized, controlled trial	46
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial	46
Associations between lifetime classic psychedelic use and markers of physical health	46
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review	45
Modulation of microglial activation by antidepressants	44
Dose–response relationships of psilocybin-induced subjective experiences in humans	44
Psychedelics and health behaviour change	42
Psilocybin microdosing does not affect emotion-related symptoms and processing: A preregistered field and lab-based study	38
Assessment of cognitive and psychomotor impairment, subjective effects, and blood THC concentrations following acute administration of oral and vaporized cannabis	38
A qualitative and quantitative account of patient’s experiences of ketamine and its antidepressant properties	38
A narrative synthesis of research with 5-MeO-DMT	35
MDMA/ecstasy use and psilocybin use are associated with lowered odds of psychological distress and suicidal thoughts in a sample of US adults	34

Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals	34
Hallucinogenic/psychedelic 5HT2A receptor agonists as rapid antidepressant therapeutics: Evidence and mechanisms of action	33
The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects	33
Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: A systematic review and meta-analysis	32
Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice	31
Adverse experiences resulting in emergency medical treatment seeking following the use of magic mushrooms	30
Prediction of MDMA response in healthy humans: a pooled analysis of placebo-controlled studies	30
Efficacy of N-methyl-D-aspartate receptor modulator augmentation in schizophrenia: A meta-analysis of randomised, placebo-controlled trials	30